Grand Pharmaceutical Group Announces First Patient Dosed in Phase III Clinical Trial of Innovative TCM for Depression
Grand Pharmaceutical Group Limited (Stock Code: 00512) has announced a significant milestone in its research and development efforts with the enrollment and dosing of the first patient in the Phase III clinical trial of its innovative traditional Chinese medicine (TCM) product, GPN01360, in China. This development marks a key step forward for the company’s pipeline and could have material implications for its future growth and share value.
Key Highlights of the Announcement
- First Patient Enrolled and Dosed: The initial patient in the Phase III clinical trial for GPN01360, a Class 1.1 innovative TCM, has been treated. The drug is intended for the treatment of depression, specifically for patients diagnosed with liver stagnation and spleen deficiency syndrome.
- Phase III Clinical Trial Details:
- The study is a randomized, double-blind, placebo-controlled, multicenter trial.
- It aims to enroll 480 patients across China, with each patient undergoing an 8-week oral treatment regimen.
- The primary endpoint is the change from baseline in the Hamilton Depression Rating Scale (HAMD-17) total score at week 8.
- Secondary endpoints include changes in the Montgomery-Asberg Depression Rating Scale (MADRS), HAMD-17 remission and response rates, Pittsburgh Sleep Quality Index (PSQI), Clinical Global Impression Scale (CGI-S and CGI-I), as well as incidence of adverse events.
- About GPN01360:
- GPN01360 is based on the classic TCM formula “Xiaoyaosan” and consists of 12 herbs including Bupleurum, Turmeric Root Tuber, and Finger Citron.
- The drug is developed for depression with symptoms such as low mood, slow thinking, decreased willpower, irritability, anxiety, insomnia, forgetfulness, poor appetite, and fatigue.
- Supported by China’s “Major New Drug Development Project”, it has demonstrated favorable safety and efficacy in Phase II, especially for depression with anxiety and insomnia symptoms.
- Market Opportunity:
- Depression is a major global public health issue, affecting 332 million people worldwide, with a prevalence of 4.0% globally and 5.7% in adults. In China, the prevalence is notably higher at 6.8%, impacting over 90 million people.
- The disorder leads to 12 billion lost workdays and nearly USD 1 trillion in economic losses annually. The current clinical cure rate is below 30%, with significant unmet medical needs due to delayed efficacy and adverse reactions from existing antidepressants.
- GPN01360 could provide a novel therapeutic option addressing these gaps.
- Company Strategy and Positioning:
- Grand Pharmaceutical is a leading integrated enterprise in China’s ENT (Ear, Nose, and Throat) drug sector, with a strong pipeline covering ophthalmology, otolaryngology, stomatology, and now expanding into chronic disease treatment such as cerebro-cardiovascular and neurological disorders.
- The company is leveraging TCM’s strengths in chronic disease management and pursuing a dual-cycle strategy for domestic and international growth.
Potential Price Sensitive Information for Shareholders
- This is a major milestone in the Group’s pipeline, representing progress toward commercialization of a potentially first-in-class TCM therapy for depression, a large and underserved market.
- The company highlights that this product is still in the R&D stage. Approval for commercialization, manufacturing, and sales is subject to various uncertainties. There is no guarantee of eventual market launch or financial benefit.
- Shareholders and potential investors should approach with caution, as successful completion of the clinical trial and regulatory approval are not assured.
Leadership and Corporate Governance
- The announcement was issued under the authority of Dr. Tang Weikun, Chairman, and the current Board comprises four executive and four independent non-executive directors.
Conclusion
This development is highly noteworthy for investors, as it signals the Group’s commitment to innovation and its capability to potentially deliver a novel solution to a large and growing market. If successful, GPN01360 could unlock substantial commercial value and enhance Grand Pharmaceutical’s leadership in both the TCM and global pharmaceutical markets.
Disclaimer
The above article is for informational purposes only. The referenced product is still under development, and there is no assurance of regulatory approval or commercial success. Investors should conduct further research and exercise caution when making investment decisions related to Grand Pharmaceutical Group Limited.
遠大醫藥集團公佈創新中藥GPN01360治療抑鬱症三期臨床試驗首位患者已入組並給藥
遠大醫藥集團有限公司（股份代號：00512）宣佈，其創新中藥產品GPN01360在中國的三期臨床試驗已成功完成首位患者入組並給藥。此舉標誌著公司研發管線的重要突破，或對未來增長及股價產生重要影響。
公告重點
- 三期臨床首位患者成功給藥： GPN01360為一類1.1創新中藥，用於治療中醫辨證為肝鬱脾虛型抑鬱症患者。
- 臨床試驗詳情：
- 隨機、雙盲、安慰劑對照、多中心三期臨床試驗。
- 計劃納入480名抑鬱症患者，每位患者口服給藥8周。
- 主要終點：8周後Hamilton抑鬱量表（HAMD-17）總分變化。
- 次要終點：Montgomery-Asberg抑鬱量表（MADRS）變化、HAMD-17緩解率及反應率、匹茲堡睡眠質量指數（PSQI）、臨床總評量表CGI-S/CGI-I變化及不良事件發生率等。
- 關於GPN01360：
- 以經典方劑“逍遙散”為基礎，結合12味中藥（如柴胡、薑黃、佛手等）現代優化研發，具有疏肝健脾、解鬱安神功效。
- 針對肝鬱脾虛型抑鬱症狀，包括情緒低落、思維遲緩、意志減退、易怒、焦慮、失眠、健忘、食慾差、疲乏等。
- 獲國家“重大新藥創制”專項重點支持，二期臨床顯示安全性和有效性良好，對伴焦慮、失眠的抑鬱症改善顯著。
- 市場機遇：
- 抑鬱症為全球重大公共衛生問題，影響3.32億人，全球患病率4.0%，成人5.7%。中國為6.8%，患者超9000萬。
- 導致每年120億工作日損失及近1萬億美元經濟損失，現有抗抑鬱藥療效延遲、副反應多，臨床治癒率不足30%，市場需求巨大。
- GPN01360有望成為新型治療選擇，填補臨床空白。
- 公司戰略與定位：
- 遠大醫藥為中國耳鼻喉領域研發、生產、銷售一體化龍頭，產品線涵蓋眼科、耳鼻喉、口腔及慢病（心腦血管、神經等）領域。
- 積極打造中成藥慢病市場，推動“全球化+雙循環”戰略，形成國內外協同新格局。
股東需注意的重要及可能影響股價的事項
- 本次三期臨床首劑給藥為公司創新藥管線的重大里程碑，若能成功上市，將打開龐大抑鬱症市場潛力，對公司未來收入及估值有積極影響。
- 惟公告強調產品仍處於研發階段，是否能最終獲批商業化存在重大不確定性，尚未有確定受益。
- 建議股東及投資者審慎評估風險，密切關注臨床結果和監管動態。
領導層及公司治理
- 公告由董事會主席唐偉坤博士發佈，現有四位執行董事及四位獨立非執行董事。
總結
本次三期臨床試驗進展對投資者極具參考價值，展示公司創新能力及在中藥和全球製藥市場的領導潛力。如能成功上市，GPN01360將為公司帶來可觀增長動能。
免責聲明
以上內容僅供參考，相關產品尚處於研發階段，最終能否獲批或商業成功尚存不確定性。投資者請進一步研究並審慎決策。
